Trials / Completed
CompletedNCT01599507
Study of FG-4592 in Subjects With Chronic Kidney Disease in China
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Sequential Group, Dose Ranging Safety and Efficacy Study of FG 4592 in Non-dialysis Chronic Kidney Disease (CKD) Subjects With Anemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 91 (actual)
- Sponsor
- Kyntra Bio · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to evaluate efficacy and safety of FG-4592 in the correction of anemia in non-dialysis chronic kidney disease patients.
Detailed description
Dose ranging study with two consecutive dose escalation cohorts. The study objective is to demonstrate that FG-4592 is effective in the correction of anemia in chronic kidney disease patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FG-4592 | TIW dosing, capsule |
| DRUG | Placebo | TIW dosing, capsule |
Timeline
- Start date
- 2011-12-01
- Primary completion
- 2013-01-01
- Completion
- 2013-01-01
- First posted
- 2012-05-16
- Last updated
- 2014-03-03
Locations
13 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01599507. Inclusion in this directory is not an endorsement.